First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study

Simple item page
dc.contributor.authorYone Pefura , Ericen_ZA
dc.contributor.authorBetyoumin, Awaen_ZA
dc.contributor.authorKengne, Andreen_ZA
dc.contributor.authorKaze Folefack, Francoisen_ZA
dc.contributor.authorNgogang, Jeanneen_ZA
dc.date.accessioned2015-11-11T12:02:44Z
dc.date.available2015-11-11T12:02:44Z
dc.date.issued2011en_ZA
dc.description.abstractBACKGROUND: Data on lipid profile derangements induced by antiretroviral treatment in Africa are scarce. The aim of this study was to determine the prevalence and characteristics of lipid profile derangements associated with first-line highly active antiretroviral therapy (ART) among Cameroonians living with human immunodeficiency virus (HIV) infection. METHODS: This cross-sectional study was conducted between November 2009 and January 2010, and involved 138 HIV patients who had never received ART (ART-naive group) and 138 others treated for at least 12 months with first line triple ART regimens that included nevirapine or efavirenz (ART group). Lipid profile was determined after overnight fast and dyslipidemia diagnosed according to the US National Cholesterol Education Program III criteria. Data comparison used chi-square test, Student t-test and logistic regressions. RESULTS: The prevalence of total cholesterol [greater than or equal to] 200 mg/dl was 37.6% and 24.6% respectively in ART group and ART-naive groups (p = 0.019). The equivalents for LDL-cholesterol [greater than or equal to] 130 mg/dl were 46.4% and 21% (p [less than or equal to] 0.001). Proportions of patients with total cholesterol/HDL-cholesterol ratio [greater than or equal to] 5 was 35.5% in ART group and 18.6% in ART-naive group (p [less than or equal to] 0.001). The distribution of HDL-cholesterol and triglycerides was similar between the two groups. In multivariable analysis adjusted for age, sex, body mass index, CD4 count and co-infection with tuberculosis, being on ART was significantly and positively associated with raised total cholesterol, LDL-cholesterol and TC/HDL cholesterol. The adjusted odd ratios (95% confidence interval, p-value) ART-treated vs. ART-naive was 1.82 (1.06-1.12, p = 0.02) for TC [greater than or equal to] 200 mg/dl; 2.99 (1.74-5.15), p < 0.0001) for LDL-cholesterol [greater than or equal to] 130 mg/dl and 1.73 (1.04-2.89, p = 0.03) for TC/HDL-cholesterol [greater than or equal to] 5. CONCLUSIONS: First-line antiretroviral therapy that includes nonnucleoside reverse transcriptase inhibitors is associated with pro-atherogenic adverse lipid profile in people with HIV-1 infection compared to untreated HIV-infected subjects in Yaounde. Lipid profile and other cardiovascular risk factors should be monitored in patients on such therapy so that any untoward effects of treatments can be optimally managed.en_ZA
dc.identifier.apacitationYone Pefura , E., Betyoumin, A., Kengne, A., Kaze Folefack, F., & Ngogang, J. (2011). First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. <i>AIDS Research and Therapy</i>, http://hdl.handle.net/11427/14896en_ZA
dc.identifier.chicagocitationYone Pefura , Eric, Awa Betyoumin, Andre Kengne, Francois Kaze Folefack, and Jeanne Ngogang "First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study." <i>AIDS Research and Therapy</i> (2011) http://hdl.handle.net/11427/14896en_ZA
dc.identifier.citationYone, E. W. P., Betyoumin, A. F., Kengne, A. P., Folefack, F. J. K., Ngogang, J., Pefura Yone, E. W., ... & Kaze Folefack, F. J. (2011). First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Res Ther, 8(33), 6405-8.en_ZA
dc.identifier.ris TY - Journal Article AU - Yone Pefura , Eric AU - Betyoumin, Awa AU - Kengne, Andre AU - Kaze Folefack, Francois AU - Ngogang, Jeanne AB - BACKGROUND: Data on lipid profile derangements induced by antiretroviral treatment in Africa are scarce. The aim of this study was to determine the prevalence and characteristics of lipid profile derangements associated with first-line highly active antiretroviral therapy (ART) among Cameroonians living with human immunodeficiency virus (HIV) infection. METHODS: This cross-sectional study was conducted between November 2009 and January 2010, and involved 138 HIV patients who had never received ART (ART-naive group) and 138 others treated for at least 12 months with first line triple ART regimens that included nevirapine or efavirenz (ART group). Lipid profile was determined after overnight fast and dyslipidemia diagnosed according to the US National Cholesterol Education Program III criteria. Data comparison used chi-square test, Student t-test and logistic regressions. RESULTS: The prevalence of total cholesterol [greater than or equal to] 200 mg/dl was 37.6% and 24.6% respectively in ART group and ART-naive groups (p = 0.019). The equivalents for LDL-cholesterol [greater than or equal to] 130 mg/dl were 46.4% and 21% (p [less than or equal to] 0.001). Proportions of patients with total cholesterol/HDL-cholesterol ratio [greater than or equal to] 5 was 35.5% in ART group and 18.6% in ART-naive group (p [less than or equal to] 0.001). The distribution of HDL-cholesterol and triglycerides was similar between the two groups. In multivariable analysis adjusted for age, sex, body mass index, CD4 count and co-infection with tuberculosis, being on ART was significantly and positively associated with raised total cholesterol, LDL-cholesterol and TC/HDL cholesterol. The adjusted odd ratios (95% confidence interval, p-value) ART-treated vs. ART-naive was 1.82 (1.06-1.12, p = 0.02) for TC [greater than or equal to] 200 mg/dl; 2.99 (1.74-5.15), p < 0.0001) for LDL-cholesterol [greater than or equal to] 130 mg/dl and 1.73 (1.04-2.89, p = 0.03) for TC/HDL-cholesterol [greater than or equal to] 5. CONCLUSIONS: First-line antiretroviral therapy that includes nonnucleoside reverse transcriptase inhibitors is associated with pro-atherogenic adverse lipid profile in people with HIV-1 infection compared to untreated HIV-infected subjects in Yaounde. Lipid profile and other cardiovascular risk factors should be monitored in patients on such therapy so that any untoward effects of treatments can be optimally managed. DA - 2011 DB - OpenUCT DO - 10.1186/1742-6405-8-33 DP - University of Cape Town J1 - AIDS Research and Therapy LK - https://open.uct.ac.za PB - University of Cape Town PY - 2011 T1 - First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study TI - First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study UR - http://hdl.handle.net/11427/14896 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/14896
dc.identifier.urihttp://dx.doi.org/10.1186/1742-6405-8-33
dc.identifier.vancouvercitationYone Pefura E, Betyoumin A, Kengne A, Kaze Folefack F, Ngogang J. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Research and Therapy. 2011; http://hdl.handle.net/11427/14896.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDepartment of Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.holder2011 Yone et al; licensee BioMed Central Ltd.en_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceAIDS Research and Therapyen_ZA
dc.source.urihttp://www.aidsrestherapy.com/en_ZA
dc.subject.otherAntiretroviral therapyen_ZA
dc.subject.otherdyslipidemiaen_ZA
dc.subject.otherHIVen_ZA
dc.subject.otherCameroonen_ZA
dc.titleFirst-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional studyen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pefura_Yone_First_line_antiretroviral_therapy_2011.pdf
Size:
301.96 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles